CDK9 and neoplasm: Our findings are in accord with recent studies that targeting of CDK9 has reduced the downstream phosphorylation of RNA Pol II at Ser2 and decreased nascent transcripts synthesis, showing promising in vitro and in vivo anti-tumor activity in carcinogenesis [8, 30].